Repligen CORP 10-Q quarterly reports

Repligen Corporation reported a 14.8% increase in total revenue for the first quarter of 2026, reaching $194.3 million, driven by strong product sales across its bioprocessing technologies.

Repligen Corporation announced a significant increase in product revenue and a return to profitability for the third quarter and first nine months of 2025, driven by acquisitions and broad portfolio growth.

Repligen Corporation reported a significant increase in second-quarter revenue and net income, driven by strong performance in its Chromatography and Analytics franchises and recent acquisitions.

Repligen Corporation reports a 10.4% increase in total revenue for Q1 2025, driven by product revenue growth and recent acquisitions.

Repligen Corporation's Q3 2024 results show a revenue increase, but the company restated prior periods due to a material accounting error related to revenue recognition.

Repligen Corporation has filed an amended quarterly report to restate its financials for the three and six months ended June 30, 2024, due to a misapplication of accounting principles related to revenue recognition and has identified material weaknesses in internal controls.

Repligen Corporation has filed an amended quarterly report to restate its Q1 2024 financials due to a misapplication of accounting principles related to revenue recognition.

Repligen Corporation has amended its third-quarter 2023 report to correct a revenue recognition error and has identified a material weakness in its internal controls.

Repligen Corporation has filed an amended 10-Q report to restate its Q2 2023 financials due to a misapplication of accounting principles related to revenue recognition.

Repligen Corporation has filed an amended quarterly report to restate its Q1 2023 financials due to a misapplication of accounting principles related to revenue recognition, also identifying a material weakness in internal controls.

Repligen Corporation's Q2 2024 results show a slight decrease in revenue and a leadership transition, with the CEO moving to Executive Chair.

Repligen Corp's first quarter 2024 results show a decrease in revenue primarily due to reduced demand related to COVID-19 and a restructuring plan, despite growth in other areas.